Undisclosed HER2×AXL bispecific ADC
/ Dong-A
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Dual targeting of HER2 and AXL by an eKiH-engineered bispecific ADC to overcome resistance in solid tumors
(AACR 2026)
- "HER2xAXL is a rationally engineered HER2×AXL bispecific ADC designed to mitigate target heterogeneity and therapy resistance. These preclinical data support investigation in HER2-expressing solid tumors—including lung, breast, and gastric cancers—particularly in patients who have failed standard first-/second-line regimens."
ADC • Bispecific • IO biomarker • Gastric Cancer • Oncology • Solid Tumor • AXL • HER-2
1 to 1
Of
1
Go to page
1